Medicamen Organics Ltd.
•₹ 24.30%
2026-08-21
PROS
- Company comfortably covers its interest (11.0x coverage)
- Company maintains a comfortable, low leverage position
CONS
- Operating cash flow has been negative in recent years
- Working capital days have increased from 82 to 175 days
* The pros and cons are machine generated based on quantitative rules.
Peer comparison
EDIT COLUMNS| S.No. | Name | CMP Rs. | P/E | Mar Cap Rs.Cr. | Div Yld % | NP Qtr Rs.Cr. | Qtr Profit Var % | Sales Qtr Rs.Cr. | Qtr Sales Var % | ROCE % | OPM % |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1. | SUNPHARMA | 1898.00 | 37.65 | 455393.78 | 0.84 | 2901.23 | 26.53 | 15299.88 | 10.98 | 19.11 | 28.81 |
| 2. | DIVISLAB | 8525.00 | 77.37 | 226311.96 | 0.35 | 902.00 | 65.50 | 3080.00 | 27.80 | 21.51 | 40.75 |
| 3. | TORNTPHARM | 5013.00 | 87.43 | 190678.41 | 0.76 | 566.00 | 3.28 | 4921.00 | 57.32 | 19.27 | 33.81 |
| 4. | CIPLA | 1416.00 | 33.94 | 114392.01 | 0.92 | 785.55 | -39.18 | 7119.28 | 4.13 | 16.00 | 16.73 |
| 5. | ZYDUSLIFE | 1105.00 | 24.42 | 110224.17 | 0.09 | 990.20 | -34.90 | 8017.00 | 23.97 | 21.39 | 24.54 |
| 6. | LUPIN | 2220.00 | 18.36 | 101506.15 | 0.81 | 1416.98 | 16.01 | 8276.89 | 34.28 | 28.86 | 29.59 |
| 7. | MANKIND | 2391.00 | 48.34 | 98747.34 | 0.04 | 574.09 | 29.12 | 4030.59 | 12.89 | 13.24 | 26.30 |
| 8. | DRREDDY | 1171.00 | 30.33 | 97740.54 | 0.68 | 435.60 | -69.10 | 8099.80 | -5.21 | 13.75 | 10.63 |
| 9. | LAURUSLABS | 1807.00 | 89.30 | 97634.42 | 0.11 | 362.07 | 123.94 | 2026.31 | 29.10 | 18.20 | 31.50 |
| 10. | AUROPHARMA | 1615.15 | 25.03 | 92932.16 | 0.25 | 1032.03 | 25.22 | 9150.35 | 17.44 | 12.76 | 20.54 |
| 11. | BIOCON | 414.30 | 136.32 | 67518.23 | 0.12 | 136.80 | 53.36 | 4336.00 | 10.89 | 3.26 | 19.54 |
| 12. | MEDIORG | 24.30 | 0.00 | 29.56 | 0.00 | — | — | — | — | 16.97 | — |
Detailed Comparison with:
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
No quarterly results found
We don't have this information yet. Please check back later.
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2024 | Mar 2025 | |
|---|---|---|
| 25 | 38 | |
| 21 | 32 | |
| Operating Profit | 6 | 7 |
| OPM % | 23 | 18 |
| Other Income | 1 | 0 |
| Interest | 1 | 1 |
| Depreciation | 1 | 1 |
| 4 | 5 | |
| Tax % | 41 | 25 |
| Net Profit | 3 | 4 |
| EPS | 3 | 3 |
| Dividend Payout % | 0 | 0 |
| Minority Interest | 0 | 0 |
| Share of Associates | 0 | 0 |
| Adjusted EPS | 3 | 3 |
| Minority Interest | 0 | 0 |
| Share of Associates | 0 | 0 |
| Adjusted EPS | 3 | 3 |
Mar 2024
- 25
- 21
- Operating Profit
- 6
- OPM %
- 23
- Other Income
- 1
- Interest
- 1
- Depreciation
- 1
- 4
- Tax %
- 41
- Net Profit
- 3
- EPS
- 3
- Dividend Payout %
- 0
- Minority Interest
- 0
- Share of Associates
- 0
- Adjusted EPS
- 3
- Minority Interest
- 0
- Share of Associates
- 0
- Adjusted EPS
- 3
Mar 2025
- 38
- 32
- Operating Profit
- 7
- OPM %
- 18
- Other Income
- 0
- Interest
- 1
- Depreciation
- 1
- 5
- Tax %
- 25
- Net Profit
- 4
- EPS
- 3
- Dividend Payout %
- 0
- Minority Interest
- 0
- Share of Associates
- 0
- Adjusted EPS
- 3
- Minority Interest
- 0
- Share of Associates
- 0
- Adjusted EPS
- 3
COMPOUNDED SALES GROWTH
- 10 Years:
- —
- 5 Years:
- —
- 3 Years:
- —
COMPOUNDED PROFIT GROWTH
- 10 Years:
- —
- 5 Years:
- —
- 3 Years:
- —
STOCK PRICE CAGR
- 10 Years:
- —
- 5 Years:
- —
- 3 Years:
- —
- 1 Year:
- 12%
RETURN ON EQUITY
- 10 Years:
- —
- 5 Years:
- —
- 3 Years:
- —
- Last Year:
- 18%
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2024 | Mar 2025 | |
|---|---|---|
| LIABILITIES | - | - |
| Equity Capital | 9 | 12 |
| 7 | 18 | |
| 12 | 12 | |
| Trade Payables | 7 | 12 |
| 4 | 6 | |
| Total Liabilities | 38 | 59 |
| ASSETS | - | - |
| 10 | 10 | |
| Capital Work in Progress | 0 | 2 |
| 6 | 7 | |
| 17 | 26 | |
| Cash & Bank | 1 | 4 |
| 5 | 9 | |
| Total Assets | 38 | 59 |
| Total Debt | 13 | 12 |
| Net Working Capital | 6 | 18 |
| Contingent Liabilities | 2 | 2 |
| Book Value per Share | 17.74 | 25.11 |
| Face Value | 10.00 | 10.00 |
| Total Debt | 13 | 12 |
| Net Working Capital | 6 | 18 |
| Contingent Liabilities | 2 | 2 |
| Book Value per Share | 17.74 | 25.11 |
| Face Value | 10.00 | 10.00 |
Mar 2024
- Equity Capital
- 9
- 7
- 12
- Trade Payables
- 7
- 4
- Total Liabilities
- 38
- 10
- Capital Work in Progress
- 0
- 6
- 17
- Cash & Bank
- 1
- 5
- Total Assets
- 38
- Total Debt
- 13
- Net Working Capital
- 6
- Contingent Liabilities
- 2
- Book Value per Share
- 17.74
- Face Value
- 10.00
- Total Debt
- 13
- Net Working Capital
- 6
- Contingent Liabilities
- 2
- Book Value per Share
- 17.74
- Face Value
- 10.00
Mar 2025
- Equity Capital
- 12
- 18
- 12
- Trade Payables
- 12
- 6
- Total Liabilities
- 59
- 10
- Capital Work in Progress
- 2
- 7
- 26
- Cash & Bank
- 4
- 9
- Total Assets
- 59
- Total Debt
- 12
- Net Working Capital
- 18
- Contingent Liabilities
- 2
- Book Value per Share
- 25.11
- Face Value
- 10.00
- Total Debt
- 12
- Net Working Capital
- 18
- Contingent Liabilities
- 2
- Book Value per Share
- 25.11
- Face Value
- 10.00
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2024 | Mar 2025 | |
|---|---|---|
| -4 | -5 | |
| Cash from Investing | -0 | -2 |
| Cash from Financing | 4 | 10 |
| 0 | 4 | |
| Free Cash Flow | -4 | -7 |
| OCF / Net Profit | -1.40 | -1.12 |
| Cumulative 5-Year FCF | 0 | 0 |
| OCF / Net Profit | -1.40 | -1.12 |
| Cumulative 5-Year FCF | 0 | 0 |
Mar 2024
- -4
- Cash from Investing
- -0
- Cash from Financing
- 4
- 0
- Free Cash Flow
- -4
- OCF / Net Profit
- -1.40
- Cumulative 5-Year FCF
- 0
- OCF / Net Profit
- -1.40
- Cumulative 5-Year FCF
- 0
Mar 2025
- -5
- Cash from Investing
- -2
- Cash from Financing
- 10
- 4
- Free Cash Flow
- -7
- OCF / Net Profit
- -1.12
- Cumulative 5-Year FCF
- 0
- OCF / Net Profit
- -1.12
- Cumulative 5-Year FCF
- 0
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2024 | Mar 2025 | |
|---|---|---|
| PER SHARE | - | - |
| EPS (₹) | 3.05 | 3.46 |
| Book Value (₹) | 17.74 | 25.11 |
| Dividend per Share (₹) | 0.00 | 0.00 |
| Cash EPS (₹) | 3.89 | 4.09 |
| PROFITABILITY | - | - |
| Operating Margin % | 18.75% | 17.32% |
| Net Margin % | 10.38% | 10.60% |
| ROE % | 17.20% | 18.13% |
| ROCE % | 18.21% | 16.97% |
| 6.83% | 8.29% | |
| EFFICIENCY | - | - |
| Debtor Days | 241 | 203 |
| Inventory Days | 89 | 65 |
| Payable Days | 282 | 286 |
| 48 | -18 | |
| FINANCIAL HEALTH | - | - |
| Debt to Equity (x) | 0.83x | 0.42x |
| Interest Coverage (x) | 7.85x | 10.99x |
| 1.26x | 1.67x | |
| GROWTH | - | - |
| Revenue Growth % | 0.00% | 51.11% |
| Operating Profit Growth % | 0.00% | 15.62% |
| Net Profit Growth % | 0.00% | 54.22% |
| 0.00% | 13.36% | |
| VALUATION | - | - |
| P/E (x) | 0.00x | 6.27x |
| P/B (x) | 0.00x | 0.86x |
| Dividend Yield % | 0.00% | 0.00% |
| 3.57x | 5.01x |
Mar 2024
- EPS (₹)
- 3.05
- Book Value (₹)
- 17.74
- Dividend per Share (₹)
- 0.00
- Cash EPS (₹)
- 3.89
- Operating Margin %
- 18.75%
- Net Margin %
- 10.38%
- ROE %
- 17.20%
- ROCE %
- 18.21%
- 6.83%
- Debtor Days
- 241
- Inventory Days
- 89
- Payable Days
- 282
- 48
- Debt to Equity (x)
- 0.83x
- Interest Coverage (x)
- 7.85x
- 1.26x
- Revenue Growth %
- 0.00%
- Operating Profit Growth %
- 0.00%
- Net Profit Growth %
- 0.00%
- 0.00%
- P/E (x)
- 0.00x
- P/B (x)
- 0.00x
- Dividend Yield %
- 0.00%
- 3.57x
Mar 2025
- EPS (₹)
- 3.46
- Book Value (₹)
- 25.11
- Dividend per Share (₹)
- 0.00
- Cash EPS (₹)
- 4.09
- Operating Margin %
- 17.32%
- Net Margin %
- 10.60%
- ROE %
- 18.13%
- ROCE %
- 16.97%
- 8.29%
- Debtor Days
- 203
- Inventory Days
- 65
- Payable Days
- 286
- -18
- Debt to Equity (x)
- 0.42x
- Interest Coverage (x)
- 10.99x
- 1.67x
- Revenue Growth %
- 51.11%
- Operating Profit Growth %
- 15.62%
- Net Profit Growth %
- 54.22%
- 13.36%
- P/E (x)
- 6.27x
- P/B (x)
- 0.86x
- Dividend Yield %
- 0.00%
- 5.01x
Documents
Announcements
Nothing filed yet.
Annual Reports
Credit Ratings
Nothing filed yet.
Concalls
Jun 2025
Nov 2024
Oct 2024